NASDAQ: ABVC - ABVC BioPharma, Inc.

Yield per half year: +158.49%
Dividend yield: 0%
Sector: Healthcare

Share chart ABVC BioPharma, Inc.


About ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

more details
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

IPO date 2017-10-11
ISIN US00091F1066
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.abvcpharma.com
Цена ао 1.15
Change price per day: -0% (1.37)
Change price per week: +13.22% (1.21)
Change price per month: +33.01% (1.03)
Change price per 3 month: +71.68% (0.798)
Change price per half year: +158.49% (0.53)
Change price per year: +59.67% (0.858)
Change price per 3 year: -31.84% (2.01)
Change price per 5 year: -51.07% (2.8)
Change price per year to date: +132.2% (0.59)

Underestimation

Title Value Grade
P/S 14.38 1
P/BV 10.11 1
P/E 0 0
EV/EBITDA -2.19 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -44.51 0
ROE, % -101.99 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.5597 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 5.35 1
Yield Ebitda, % -47.04 0
Yield EPS, % -92.64 0
Total: 0.2



Head Job title Payment Year of birth
Mr. Eugene Jiang Chairman & Chief Business Officer 200k 1986 (39 years)
Dr. Tsung-Shann Jiang EMBA, Ph.D. Chief Scientific Officer, Chief Strategy Officer & Director 200k 1954 (71 year)
Dr. Uttam Yashwant Patil Ph.D. CEO & Interim CFO N/A 1986 (39 years)

Address: United States, Fremont. CA, 44370 Old Warm Springs Boulevard - open in Google maps, open in Yandex maps
Website: https://www.abvcpharma.com